afmd.... someone once asked me to look at it. Looked ok, boring. And I had bets on bispecifics. So I didn't have much interest.
Then along came Genentech. Now I'm wondering, is THIS is the car-t killer. Probably not, but it's not like Genentech can't make bispecifics.
EV is about 65-70m. Major shareholders are the kids of deceased founder of SAP. They've been selling for a few months, but they've still got 6m shares, last disclosure. Feels like they've been selling into the recent bad news (trial death). EV is about the same as just before the Genentech deal, when company was left for dead. 96m in upfront and other near-term cash added, EV pretty much the same. Half of EV cut overnight on news of death. CD19-targeted T cells are a bitch.
ASH presentation coming, lotsa biobucks that weren't there.
But the kids are dumping, dumping, dumping. They want dad's money! I presume that we'll see that chunk dwindle to about 3-4m, and that it will go suddenly, in manageable blocks. |
